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Generating insulin-producing β-cells from human induced pluripotent stem cells is a
promising cell replacement therapy for improving or curing insulin-dependent diabetes.
The transplantation of end-stages differentiating cells into living hosts was demonstrated
to improve β-cell maturation. Nevertheless, the cellular and molecular mechanisms
outlining the transplanted cells’ response to the in vivo environment are still to
be properly characterized. Here we use global proteomics and large-scale imaging
techniques to demultiplex and filter the cellular processes and molecular signatures
modulated by the immediate in vivo effect. We show that in vivo exposure swiftly
confines in vitro generated human pancreatic progenitors to single hormone expression.
The global proteome landscape of the transplanted cells was closer to native human
islets, especially in regard to energy metabolism and redox balance. Moreover, our study
indicates a possible link between these processes and certain epigenetic regulators
involved in cell identity. Pathway analysis predicted HNF1A and HNF4A as key regulators
controlling the in vivo islet-promoting response, with experimental evidence suggesting
their involvement in confining islet cell fate following xeno-transplantation.
Keywords: cell identity, cell fate, differentiation, endocrine progenitors, signaling, pathway analyses
INTRODUCTION
Loss of insulin-producing pancreatic β-cells ultimately characterize most diabetic conditions,
prompting extensive efforts aimed at replenishing these cells from either endogenous (Chera and
Herrera, 2016; Zhou and Melton, 2018) or exogenous sources (Balboa and Otonkoski, 2015). As
part of the latter strategies, the employment of human induced pluripotent stem cells (hiPSC)
as a source for insulin-producing cells has gained a lot of momentum in the recent years (Loo
et al., 2018; Odorico et al., 2018). These methods are based on a stepwise hiPSC differentiation
strategy mirroring the stages characterizing β-cells fate acquisition during development (Pagliuca
and Melton, 2013; Melton, 2016; Petersen et al., 2018).
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Despite generating insulin-producing cells with varying
degrees of functional maturity, most current protocols present
heterogeneous outputs, also producing cells secreting other
pancreatic islet hormones (Petersen et al., 2017; Vethe et al.,
2017). Moreover, some of the differentiating cells presents
a hybrid phenotype, expressing more than one hormone
(Bruin et al., 2014; Petersen et al., 2017; Vethe et al., 2017).
This is in stark contrast to the bona fide human islet cells,
which in homeostatic conditions are restricted to secrete a
single pancreatic hormone: glucagon (α-cells), insulin (β-cells),
somatostatin (δ-cells), pancreatic polypeptide (PP/γ-cells)
or ghrelin (ε-cells) (Herrera, 2000; Desgraz and Herrera,
2009). The ambiguous hormone selection presented by the
cells differentiated in vitro represents an important problem
(Kushner et al., 2014), as this is usually connected with
functional immaturity. Consequently, many differentiation
protocols were aimed at improving the monohormonal cell
fractions. Recent studies (Nair et al., 2019; Velazco-Cruz et al.,
2019) report novel embryonic stem cells (ESC) differentiation
strategies leading to substantial improvements of β-cell
maturation and functionality. Indeed, these ESC-derived
β-cells presented an energy metabolism fingerprint and glucose
stimulated insulin secretion similar to the one observed
in human islets.
In addition, xeno-transplantation into living hosts, such as
mice, has been shown to significantly increase the yield and
functionality of the differentiating hPS-derived cells (Kroon
et al., 2008; Rezania et al., 2012, 2014; Pagliuca et al., 2014).
Indeed, after extensive periods of time (2–6 months), the
xenotransplantation of circa two million in vitro differentiated
cells was able to normalize the glycemia in diabetic mice (Pagliuca
et al., 2014; Rezania et al., 2014; Agulnick et al., 2015; Vegas
et al., 2016; Bochenek et al., 2018; Saber et al., 2018). Although
these experiments highlighted the importance of the in vivo
environment and its systemic factors in promoting islet cell
fate, the signals governing this process are largely unknown.
Moreover, the graft response to the in vivo environment was not
yet properly characterized.
In this study we aimed to address this knowledge gap
by demultiplexing and characterizing the initial response of
the hiPSC-derived differentiating pancreatic progenitors to
the in vivo environment, using global proteomics and large-
scale imaging techniques. Here we show that the in vivo
exposure rapidly routes a large fraction of human pancreatic
progenitors toward single hormone expression. Moreover, the
overall proteome landscape of the transplanted cells was closer
to a native islet-like regulation pattern and especially the energy
metabolism and redox signature. Our study suggests a potential
link between these, and the improvement of hormone selection
through regulation of epigenetic factors involved in maintaining
and propagating the patterns of hormone expression. Last, we
identified by pathway analysis two upstream regulators, HNF1A
and HNF4A predicted to be responsible for the in vivo islet
promoting response of the transplanted cells and experimentally
confirmed their role in confining human pancreatic progenitors
to single hormone expression.
MATERIALS AND METHODS
Cell Sources and Ethics Statements
The Norwegian Regional Committee of Medical and Health
Research Ethics approved the reported experimental protocols
used for hiPSCs (REK 2010/2295) and for human islets (REK
2011/426). All methods were carried out in accordance with
the Helsinki Declaration. Informed consent was obtained from
the healthy and MODY1/3 patient donors (skin fibroblasts)
or from the relatives (organ donations). The human induced
pluripotent stem cells (hiPSCs) used in this paper were generated
using episomal reprograming with vectors from Addgene
#27077 (OCT3/4), #27080 (L-MYC, LIN28) and #27078 (SOX2,
KLF4) as previously described by us (Vethe et al., 2017;
Bjørlykke et al., 2019). Proteomic analyses of HNF1α1/+ was
performed on cell lines generated by Sendai reprograming
carried out by Tekara Bio Inc., using a CytoTune-iPS 2.0
Sendai reprogramming kit (#A16517, Life Technologies) as
described in Bjørlykke et al. (2019). All hiPSC lines were
negative for mycoplasma, by using MycoAlert Mycoplasm
Detection Kit (Lonza, LT07-418). Seven distinct iPSC lines
were used in the study. The pluripotency of the iPSC lines
was previously tested (Vethe et al., 2017; Bjørlykke et al.,
2019), while their differentiation potential was previously
assessed in Vethe et al. (2017), Legoy et al. (2019), Vethe
et al. (2019a). Human islets were obtained as previously
described (Friberg et al., 2008) from seven deceased donors
(males and females).
Cell Preparation
The hiPSC lines were enriched for SSEA4+ cells using
magnetic beads (#130097855 MACS Miltenyi Biotec) before
in vitro differentiation. Both normal and mutated hiPSCs were
differentiated according to a seven-stage protocol (Rezania
et al., 2014). The planar differentiation efficiencies estimated
as insulin+ NKX6.1+ co-expressing cells were similar with
the previously reported values (Supplementary Figure S1A).
Also, this percentage was similar between WT and HNF1A1/+
in two independent differentiation rounds (Supplementary
Figure S2L). The differentiation efficiencies for HNF4A1/+
clones was previously assessed in Vethe et al. (2017) and
consequently assumed similar in this work. For this study we
used 2D differentiation on Matrigel-coated plates until Stage
5 (S5; pancreatic endocrine precursors), or up to Stage 7 (S7;
maturing beta-cells), S5 cells were encapsulated in alginate
before continued differentiation toward S7, and S5 and S7
cells encapsulated in alginate prior to in vivo transplantation.
Alginate encapsulation was performed as we have described
earlier (Vethe et al., 2019b). Cell number and viability was
measured as previously described (Vethe et al., 2019b). Cell
viability mean was 86.53 ± 7.03%. The fraction of dying
cells at different time points following transplantation in
normoglycemic animals was similar to the previously reported
(Legoy et al., 2019) and was estimated at ∼7.5% between
1- and 4-weeks postTX.
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Flow Cytometry Analysis
Differentiating cells from stage 5 (pancreatic endocrine
precursors) or stage 7 (maturing beta cells), were collected
using TrypleTM Select Enzyme (1X). Cells were first checked
for viability using NucleoCounter R© NC-200TM (Dąbrowskiego,
Poznań, Poland), and only more than 80% viable cells were used
in the assay. Cells were washed and incubated in a 96-well plate
(v-bottom, 2× 105 cells per well) with Fixation/Permeabilization
solution 20 min. After washing with Perm/Wash Buffer, cells
were stained for 45 min in the dark at RT with FITC-conjugated
anti-insulin and AF647-conjugated anti-NKX6.1. Markers were
set according to the isotype control FITC or AF647-conjugated
mouse IgG1. After washing in PBS, the cells were examined on a
flow cytometer (BD LSRFortessa, Becton-Dickinson Biosciences,
San Jose, CA, United States). Gating was performed according to
the isotype control. FACS analysis was done using FlowJo (Flow
cytometry analysis software, Ashland, OR, United States).
Transplantation
For transplantation we used the following transgenic mouse line
NOD.Cg-PrkdcscidIl2rgtm1Wjl Tg (Ins2-HBEGF) 6832Ugfm/Sz
(Yang et al., 2015) referred to as NSG RIP-DTR. Three mice (8–
12 weeks old) were used for each group. The mice for the diabetic
group received diphtheria toxin injections intraperitoneal (ip) as
previously described (Thorel et al., 2010; Cigliola et al., 2018).
Glycemia were measured two times per week with a Contour
XT glucometer (Bayer). The mice received transplantation of
alginate beads intraperitoneally when anesthetized with inhalable
sevoflurane administered via Datex-Ohmeda Sevotec 5. Each
mouse was transplanted with approximately five million cells.
Transplanted mice received 0.5 mg/ml paracetamol in the
drinking water for 5 days post-transplant. At the end of in vivo
incubation of the transplanted cells, mice were euthanized by
cervical dislocation and the alginate beads were collected from
the intraperitoneal cavity by lavage. Beads were rapidly washed
in saline solution for removing traces of blood and host tissue
and either immediately fixed in 4% PFA or transferred in lysis
buffer for proteomics. All animal procedures were performed
in accordance with the EU Directive 2010/63/EU for animal
experiments. The breeding strategy and experimental protocols
were approved by the Norwegian Animal Research Authority
(FOTS IDs 8329 and 8423). The mice were housed in individually
ventilated cages (IVC) enriched with wooden bedding, nesting
material, in a temperature-controlled environment at 22◦C under
a 12-h light-dark cycle. The mice were given ad libitum access to
water and standard diet RM1A (SDS).
Immunofluorescence
Preparation and immunofluorescence of alginate beads were
performed as previously described (Vethe et al., 2019b). The
pancreas from the mice were fixed for 2 h in 4% PFA,
before dehydration using a sucrose gradient of 10, 20, and
30% and embedded in Tissue Tek OCT compound (Sakura
JP). Sections of 10 µm were obtained with a cryotome (Leica
CM 1950, Leica, DE) and added on SuperFrost Plus slides
(Thermo Scientific). The immunofluorescence staining was
performed following indications provided by the supplier. The
following primary antibodies were used: mouse anti-insulin IgG1
(1/500, I2018, Sigma-Aldrich), guinea-pig anti-porcine insulin
(1/400, A056401-2, Dako), mouse anti-porcine glucagon (1/1000,
G2654, Sigma-Aldrich). The following secondary antibodies
were used at dilution 1/500: goat anti-mouse IgG1 A488, goat
anti-guinea-pig A488, goat anti-guinea-pig A546, goat anti-
mouse IgG1 A546. DAPI (1/1000, D1306, Molecular Probes)
was used to stain the nuclei. The samples were mounted
in Prolong Diamond Antifade Mountant Media (P36970, Life
technologies). Image acquisition and analysis was performed on
Andor Dragonfly confocal microscope and Imaris 9.1.2 (Bitplane
AG) as we have previously described (Vethe et al., 2019b).
We also performed manual counting on images acquired using
a 40x immersion objective on Leica TCS SP5 confocal (Leica
Microsystems CMS GmbH).
Global Proteomics Analysis
The proteomics analysis for the in vitro samples and associated
human islets were performed as we have earlier described
(Vethe et al., 2019b) dataset identifier PXD012704, with the
exception of the HNF1α1/+ samples which were performed
as in Vethe et al. (2017). Protein samples from the in vivo
transplanted cells were processed for Tandem Mass Tag (TMT)
11-plex as for the in vitro samples, apart from the use of
halved volume of TMT reagents. A total of 12 fractions were
collected from the pooled TMT-labeled peptide samples using
the Pierce High pH Reversed-Phase Peptide Fractionation Kit
(cat. # 84868) and 7.5, 10, 12.5, 15, 17.5, 20, 22.5, 25, 27.5,
30, 35, and 60% acetonitrile. Every sixth of these fractions
were combined to yield six fractions in total. Subsequently
we acidified the samples using 1% formic acid before vacuum
centrifuged to near dryness. Each fraction was desalted using
StageTip, dried via vacuum centrifugation, and reconstituted
for LC-MS/MS processing. For LC-MS3 analysis ∼5 µg from
each fraction was dissolved in 15% aqueous formic acid/5%
acetonitrile prior to loading on an Orbitrap Fusion Lumos
mass spectrometer (Thermo Fisher Scientific, San Jose, CA,
United States) coupled to a Proxeon EASY-nLC 1200 liquid
chromatography (LC) pump (Thermo Fisher Scientific). By using
a 100-µm inner diameter microcapillary column packed with
∼35 cm of Accucore resin (2.6 µm, 150 Å, ThermoFisher
Scientific) the peptides were fractionated. We loaded ∼1 µg
onto the column for each analysis. Subsequent separation and
acquisition were performed as previously described (Vethe et al.,
2019b). Samples were analyzed in duplicate, one with advanced
peak determination (ADP) activated and a second run with
this option off. Both analyses used the real-time search (RTS)
algorithm (Erickson et al., 2019). Data was searched against
the UniProt human database (downloaded: October, 2016). The
dataset was uploaded to ProteomeXchange via the PRIDE1
partner repository with the dataset identifier PXD015955. The
hyperglycemia samples from this dataset were not analyzed in
this work. Two human islets samples were excluded from analysis
due to islet quality problems.
1http://www.proteomexchange.org
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Proteomic Data Analysis
We analyzed the mass spectrometry data as earlier described
(Vethe et al., 2019b). Protein quantify values were analyzed
using Microsoft Excel and GraphPad Prism (version 8).
Hierarchical clustering was performed using with GeneSpring
14.9.1 GX software (Agilent), with clustering on both entities
and conditions by using Squared Euclidian distance metric
and Ward’s linkage rule. The pathway analyses were generated
by QIAGEN’s Ingenuity Pathway Analysis program (IPA R©,
QIAGEN, Redwood City, United States)2 (Kramer et al., 2014)
as previously described (Vethe et al., 2019b), here using 35
molecules/network; 25 networks/analysis for generating the
interaction networks.
Statistical Analysis
For the immunofluorescence counting we used Mann-Whitney
non-parametric test to compare the number of hormonal
cells between the different groups using GraphPad Prism
v8.1.2. Also, unpaired two-tailed Student’s t-tests were used
for analyzing the proteomics data. A p-value of <0.05 was
considered significant.
RESULTS
Short-Term Exposure of Encapsulated
Pancreas Progenitor Cells to in vivo
Environment Promotes an Islet-Like
Signature
To investigate the short-term effect of the in vivo environment
on islet cell differentiation, we xenotransplanted encapsulated
hiPSC-derived pancreas progenitors (from here on S5-
cells) into the intraperitoneal cavity of humanized NSG
mice (Supplementary Figure S1B). Based on its consistent
reproducibility and popularity, we employed an established
protocol (Rezania et al., 2014) for the initial directed
differentiation (in vitro). The resulting S5-cells (five million
cells) were encapsulated in alginate and then immediately
transplanted into normoglycemic mice for 2 weeks (in vivo),
a period of time equivalent to the one required for generating
maturing islet cells in vitro (2 weeks).
As the mechanical forces elicited by the encapsulation of
cells can in itself interact with the differentiation response to
the differentiation cocktails (Vethe et al., 2019b), we used an
array of experimental conditions aimed to ultimately demultiplex
the in vivo-specific molecular mechanisms stimulating the islet
cell fate acquisition program (Figure 1A). As such, pancreas
progenitors (S5-cells) were differentiated toward islet cell fates (1)
in vitro on Matrigel-coated plates (planar 2D culture condition;
termed “ S7-cells”), (2) in vitro in alginate capsules (termed
“S7enc[S5-S7]′′) and (3) in vivo following xenotransplantation
(termed “2w_postTX”). In this setup, the comparative analysis
of the molecular signatures exhibited by the resulted end-stage
2www.qiagen.com/ingenuity
cellular entities grants the possibility of discriminating between
the effects of the (i) differentiation cocktail, (ii) encapsulation,
(iii) in vivo environment.
We first performed global proteomics on the S5 cells,
their respective differentiation counterparts (S7, S7enc[S5-S7],
2w_postTX cells) and human islets isolated from cadaveric
donors. 2369 proteins were detected in all conditions across
TMT-plexes (Supplementary Figure S1C). About two thirds
(64.83%, 1536/2369) represented differentially expressed proteins
(DEPs) between the S5-cells (pancreatic progenitors) and the
directed differentiation goal, the bona fide human islet cells
(FC ≥ 1.5, p < 0.05). The principal component analysis
(PCA) revealed a clear separation of the samples according
to the differentiation strategy (Principal Condition 1: 40.48%).
The 2w_postTX cluster of samples exhibited the highest
similarity with human islets (Supplementary Figure S1D,
green). The hierarchical clustering confirmed these results,
as the recovered xenotransplanted cells branched closer to
human islets (Supplementary Figure S1E). Furthermore, a
direct comparison of these sets revealed that 14.78% (227/1536)
proteins were differentially expressed between transplanted
cells and islets. These results indicate that a relevant number
of proteins changed their pattern of expression toward an
islet-like signature even after just a brief exposure to the
in vivo environment.
Short-Term Exposure to in vivo
Environment Increases the Abundance
of the Main Islet Hormones
Based on their islet-normalized profile, 738, 1110 and
respectively, 1055 proteins exhibited a significant change of
their regulatory dynamic (FC ≥ 1.5, p < 0.05) in response
to the distinct differentiation conditions described above
(Figure 1A, Supplementary Figure S1F, and Supplementary
Table S1). Among the 1055 DEPs regulated following 2 weeks
of transplantation, the main islet-specific hormones, insulin,
glucagon and somatostatin were significantly upregulated,
with glucagon displaying the highest increase (Figure 1B).
Interestingly, glucagon expression was promoted by all
differentiation conditions, while insulin and somatostatin
were promoted only by the 3D settings (in vitro and in vivo
encapsulated conditions). In contrast, the pancreatic polypeptide,
a hormone produced by the pancreatic PP/γ-cells, was not
promoted in the transplanted samples, being significantly
regulated solely in the in vitro differentiating capsules
(S7enc[S5-S7]). Last, the pan-endocrine marker Chromogranin A
(CHGA), which exhibited increased abundance in the in vitro
setups, was not significantly regulated in vivo (Figure 1B).
These data suggest that even short exposure of S5 cells to
the in vivo environment is enough to increase the expression of
the three main islet hormones, including insulin. Nevertheless,
it is not sufficient for induction of pan-endocrine markers
such as CHGA. This indicates that the brief exposure to the
in vivo environment promotes hormone production in the
differentiating cells, but is probably insufficient for recruiting new
progenitors toward the endocrine program.
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FIGURE 1 | Assessment of the pancreatic islet hormones expression by global proteomics and large-scale imaging following three distinct differentiation strategies
(A) Experimental design depicting the three differentiation strategies considered. Numbers in bold represent differentially expressed proteins (DEPs) between the final
differentiation stage (S7, S7enc[S5-S7], 2w_postTX) and pancreatic progenitors (S5), following islet-standard normalization (data represent two distinct TMT-11 plexes).
(B) Graphs displaying the statistically significant (FC ≥ 1.5, p < 0.05) regulated islet hormones (colored bars) identified in the DEPs set characterizing each
differentiation strategy (in vitro Matrigel differentiation – chartreuse, in vitro encapsulation – yellow and in vivo transplantation of encapsulated cells – light green).
(C) 3D reconstructions of dragonfly imaged whole alginate capsules containing cells immunofluorescently labeled for insulin (green), glucagon (red) and DAPI (blue) in
the four conditions analyzed (scale bar 200 µm, gamma correction 0.4). (D) Proportion of monohormonal glucagon cells in the four distinct populations analyzed
(n = 9,18,18,18) and the high magnification of a representative encapsulated glucagon+ cell. (E) Proportion of monohormonal insulin in the four distinct populations
analyzed (n = 9,18,18,18) and the high magnification of a representative encapsulated insulin+ cell. (F) Proportion of bihormonal cells (insulin+glucagon+
co-expressing) and a high magnification of a representative encapsulated bihormonal cell. High magnification scale bars: 5 µm. Graphs data are shown as box plot
mean to max values. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 (Mann–Whitney test). Abbreviations: TX, transplant; 2D, Matrigel differentiation; 3D,
alginate encapsulation; DEPs, differentially expressed proteins; Dt, time interval; FC, fold change; S5-cells, stage 5 cells (pancreatic progenitor stage); S7-cells, stage
7 cells (maturing β-cells); S7enc[S5-S7], differentiated in capsules from stage 5 to stage 7; 2w_postTX, 2 weeks following transplantation (differentiation in mice).
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Short-Term Exposure to in vivo
Environment Does Not Increase the
Hormone Positive Fraction but Improves
Their Monohormonal Identity
To discriminate if the brief in vivo exposure increases the
fraction of hormone positive cells as opposed to improving
the hormone production in the transplanted encapsulated cells,
we performed large scale imaging microscopy of the three
differentiation conditions. To allow the use of similar counting
algorithms, a similar number of the cells differentiated in the
planar 2D setup (S7-cells) were fixed and encapsulated just
before image acquisition (Figure 1C). Briefly, for each capsule
a mosaic of nine fields of view (FoV) over 100 z-planes were
acquired, reconstructed and automatically quantified by using
Imaris 9.1.2 as previously described by us (Vethe et al., 2019b).
The quantification revealed the rise of the monohormonal
glucagon+ (Figure 1D) and insulin+ (Figure 1E) fraction in
the encapsulated cells following brief exposure to the in vivo
environment (compare 2w_postTX and S5 columns). Moreover,
this was coupled with a significant decrease in the proportion
of immature bihormonal cells (Figure 1F). Overall, these results
corroborate that rather than increasing the number of hormone
expressing cells, the in vivo transplantation enhances the quality
of the differentiated encapsulated cells. This is probably achieved
by refining the accuracy of cell fate/hormone status selection and
improving hormone production.
The Demultiplexed in vivo Effect
Promotes Oxidative Phosphorylation and
Neuritogenesis
Further, to globally characterize the response to the in vivo
environment besides islet hormone regulation, we first
discriminated the in vivo effect signature and subsequently
performed pathway analysis.
As the S5-cells are encapsulated before transplantation to
protect against the immune attack as well as to allow their
retrieval, the above results reflect the combinatorial impact
of both alginate encapsulation and in vivo environment. To
focus exclusively on the latter (in vivo effect), the readout
of the three differentiation setups was used to accurately
exclude the encapsulation effect. First, to comprehensively define
the protein set significantly regulated by encapsulation, we
compared the two in vitro conditions, i.e. standard differentiation
(differentiation cocktail effect) and cells differentiating in
capsules (differentiation cocktail and encapsulation effect)
(Figure 2A). The Venn comparison revealed 582 DEPs
being modulated exclusively as a result of the encapsulation
effect. Moreover, although 528 DEPs were found regulated
by both conditions, about three quarters (76.70%, 405/528
DEPs) displayed distinct regulatory patterns according to the
differentiation setup (FC ≥ 1.5 of difference). This indicates
that despite being mainly targets of the differentiation cocktail,
their regulation is also significantly influenced by encapsulation
and thus likewise a consequence of this effect. Subsequently, the
overall encapsulation effect signature was compared against the
in vivo differentiation setup. The Venn diagram filtered 307 DEPs
regulated solely by the in vivo effect, while 489 shared a common,
however, differential, regulation of the encapsulation and in vivo
effects (Figure 2A and Supplementary Table S2).
To identify the protein networks, signaling pathways
and upstream regulators characterizing the overall in vivo
environment signature, we performed pathway analysis on the
resulted in vivo effect protein set (Supplementary Table S2).
The Ingenuity Pathway Analysis (IPA) software revealed a strong
energy metabolism (Supplementary Figure S2A), with pathways
such as oxidative phosphorylation (OXPHOS) being confidently
predicted as activated following transplantation (Figure 2B). This
is suggestive of the impact of transplantation on the redox balance
of the differentiating cells. Furthermore, the analysis identified
the Hepatocyte nuclear factor 1-alpha (HNF1A) transcription
factor as the leading activated upstream regulator responsible for
the observed regulatory landscape (Supplementary Figure S2B).
Of note, in the top activated transcriptional regulators the
program inferred the involvement of transcription factors
involved in the pancreatic islet development (Hepatocyte nuclear
Factor 4A – HNF4A and Pancreas transcription factor 1A –
PTF1A), as well as cellular senescence and growth (Cyclin-
dependent kinase inhibitor 2A – CDKN2A and Forkhead box
protein O3 - FOXO3), suggesting the role of the in vivo niche
on islet cell fate decision, consistent with the above observations
(Figure 2C and Supplementary Figure S2C).
Interestingly, the disease and function analysis pinpointed
with high confidence the decrease of both synthesis and
production of active oxygen species (Figure 2D and
Supplementary Figure S2D), which combined with the
observed increase of OXPHOS and low antioxidant activity
(Figure 2B), advocate a scenario consistent with an improvement
of the energy metabolism of the differentiating cells following
transplantation and not a tilt of the redox balance toward
oxidative stress.
Aside from the energy metabolism signature, the analysis
predicted a decrease in the cholesterol metabolism and an
activation of vitamin metabolism in the transplanted cells
(Supplementary Figure S2D). Moreover, a robust activation
of a neurogenesis/neuritogenesis signature was supported by a
large fraction of the data set (Figure 2E and Supplementary
Figure S2E), which combined with the short transplantation
period argue in favor of the transplanted differentiating cells
(graft) stimulating the innervation from the niche. This is similar
to islet cells transplanted underneath the kidney capsule, known
to promote the innervation of the graft in the first weeks following
transplantation (Korsgren et al., 1993; Tang et al., 2014).
The in vivo Environment Shifts the
Energy Metabolism Signature of the
Transplanted Cells Toward Native Islet
Regulation
To assess if the observed proteome landscape changes
induced by the in vivo effect lead to an improved islet-like
signature, we focused on differentially expressed proteins
that following in vivo exposure are regulated toward the
abundance levels normally detected in native islets (Figure 3A).
About half of the proteins encompassed by the in vivo effect
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FIGURE 2 | Pathway analysis of the proteome landscape following in vivo exposure. (A) Analysis workflow depicting the strategy used for demultiplexing the in vivo
effect (B) IPA-generated top canonical pathways with predicted regulation (z-score ≥ 1.1) characterizing the in vivo response. (C) Top predicted activated upstream
transcription regulators and the HNF1A target molecules observed regulated in the in vivo effect DEPs dataset. (D,E) IPA-generated networks and graph
representations of selected dataset DEPs characterizing the corresponding top disease and function processes. Abbreviations: TX, transplant; DEPs, differentially
expressed proteins; FC, fold change; S5-cells, stage 5 cells (pancreatic progenitor stage); S7-cells, stage 7 cells (maturing β-cells); S7enc[S5-S7], differentiated in
capsules from stage 5 to stage 7; 2w_postTX, 2 weeks following transplantation (differentiation in mice), Path, pathway. For abbreviations see Supplementary
Table S3.
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(56.53% 450/796, Supplementary Table S2) presented an
islet-promoting regulation, with ∼22.23% (177/796) reaching
islet abundance values. Most (63.11% 284/450) were upregulated,
i.e. characterized by low abundance in S5-cells, as compared
to islets followed by an increase toward islet abundance levels
following transplantation (Figure 3A, lower quadrant).
The pathway analysis of the protein subset exhibiting islet-
promoting regulation revealed that the proteins defining the
energy metabolism signature detected above are encompassed
in this group (Figure 3B and Supplementary Figure S2F). This
suggests that transplantation improves the energetic status of the
cells toward the one presented by native islets. The evaluation
of the observed regulatory landscape pointed once again to
HNF1A as top activated upstream regulator (Supplementary
Figure S2G), while RICTOR (Rapamycin-insensitive companion
of mTOR) was predicted as top inhibited (Supplementary
Figure S2H). In addition, the activation of transcription factors
with function in islet development and growth, such as HNF4A
or FOXO3, was reiterated in this context, suggesting that the
protein signatures defined by these regulators contribute to the
acquisition of an islet-like phenotype. Indeed, the vast majority of
the proteins compatible with HNF1A (94.44%), HNF4A (68.75%)
and FOXO3 (69.23%) regulation responded to the in vivo effect
by following an islet-promoting regulation (Figure 3C and
Supplementary Figure S2I).
Correspondingly, the comparative overall disease and
function analysis inferred the signature of oxidative stress
inhibition to be orchestrated by proteins displaying an islet-
promoting regulation in response to the in vivo environment
(Figure 3D, red cassette). Moreover, an active glycolysis and
oxygen consumption was also predicted based on the proteins
belonging to this subset, strengthening the assertion of an
improved energetic and metabolic status of the cells following
transplantation (Figure 3D, yellow cassette). In contrast,
the neurogenesis/neuritogenesis signature identified in the
overall in vivo effect was not detected in the islet-promoting
subset (Figure 3D, blue cassette), indicating that the proteins
characterizing this signature do not contribute directly to the
acquisition of an islet-like cell fate, rather fulfill a maintenance
role required for the graft adaptation and survival in the
transplantation niche.
Of note, Neuroendocrine convertase 1 (PCSK1, +24.30×,
p = 0.0002) and 2 (PCSK2, +7.31×, p = 0.0073) the key
neuroendocrine convertases responsible for insulin, glucagon
and somatostatin processing were amongst the significantly
upregulated proteins displaying a sustained islet-promoting
regulation toward values presented in native islets. Similarly, the
levels of SOD1 (superoxide dismutase 1, +2.372× p = 0.0177)
and SOD2 (superoxide dismutase 2, +2.068×, p = 0.0074),
essential for destructing superoxide radicals and maintaining
the cell redox balance, displayed improved abundance levels,
closer to the ones detected in human islets. Finally, proteins
involved in synthesis of reactive oxygen species, such as
PIN1 (Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1,
−5.08×, p = 0.0007) and PXDN (Peroxidasin homolog,−6.05×,
p = 0.0430) presented a steep decrease toward islet abundance
levels following transplantation (Figure 3E).
Overall, these results suggest an improvement of the redox
balance, glucose and energy metabolism in the transplanted cells
in response to in vivo exposure. In contrast, other processes
stimulated by the in vivo niche, such as neuritogenesis, do
not follow a trend compatible to the islet cell fate acquisition,
although they might, however, have an essential role in
the graft survival.
Improved Energy Metabolism Status Is
Linked to Enhanced Expression of
Epigenetic Modifiers Involved in Cell
Fate Restriction
To investigate if the improved energetic signature could be
related to the observed improvement of cell fate selection in the
transplanted cells, we performed network analysis on the protein
subset exhibiting islet-promoting regulation with a focus on
modulated epigenetic modifiers. We identified in the dataset four
DEPs with known epigenetic role (Supplementary Figure S2J).
Further inquiry revealed the upregulation of MECP2 (Methyl-
CpG-binding protein 2, 1.74×, p = 0.0458) in the in vivo exposed
cells, a key enzyme involved in maintaining the repression
of α-cell fate in β-cells (Dhawan et al., 2011). This enzyme
acts by binding the methylated locus of the essential α-cell
determinant gene, ARX (Aristaless-related homeobox), in β-cells,
thus preventing its expression in the insulin producing cells.
Previous studies demonstrated the importance of MECP2 for
restricting hormone selection as its loss results in misexpression
of key α-cell markers such as MAFB (V-maf musculoaponeurotic
fibrosarcoma oncogene homolog) or glucagon in murine β-cells.
Consequently, the detected improved expression of this enzyme
is consistent with the observed decrease of the bihormonal
fraction. Unfortunately, due to inherent sensitivity issues related
to performing proteomics on encapsulated samples, we were
unable to confirm ARX or MAFB decrease as a consequence of
MECP2 activation in the transplanted cells. Of note, as MAFB
retains its expression in mature human β-cells (Conrad et al.,
2016; Cyphert et al., 2019), it is possible that its regulation is
not affected in the human context. Interestingly, MECP2 was
organically networked with regulated proteins involved in the
lipid and energy metabolism (Figure 3F), suggesting a link
between the improved energetic status of the transplanted cells
and its upregulation.
The in vivo Exposure Effect on Cell Fate
Restriction Is Mediated by HNF1A and
HNF4A Induction
Since the above analyses predicted a central role for HNF1A for
the observed proteome landscape response to in vivo exposure,
we focused on validating its role in islet cell fate decisions
following transplantation. As to our knowledge there are no
available pharmacological agents for modulating HNF1A activity,
we employed hiPSC cells derived from Norwegian patients
bearing a dominant heterozygous mutation (hot-spot mutation
P291fsinsC) in the HNF1A (Bjorkhaug et al., 2003).
We first differentiated HNF1α1/+ hiPSC toward S5-
cells, followed by encapsulation and xenotransplantation
Frontiers in Cell and Developmental Biology | www.frontiersin.org 8 February 2020 | Volume 8 | Article 109
fcell-08-00109 February 22, 2020 Time: 17:25 # 9
Legøy et al. Human Pancreatic Progenitors Monohormonal Identity
FIGURE 3 | Pathway analysis of proteins following islet-promoting regulation patterns as result of the in vivo effect. (A) Scheme depicting the selection strategy and
waffle charts reflecting the number of proteins showing a dynamic of regulations compatible with an islet-promoting pattern in response to the in vivo effect. The
scheme circles reflect the regulation reported to the islet abundance levels. Arrows represent the generic mandatory direction of regulation for inclusion in the
islet-promoting signature (blue – downregulation, yellow – upregulation). The waffle graph dots reflect the regulation dynamic following transplantation (similar to the
scheme arrows) (B) IPA-generated top canonical pathways with predicted regulation (z-score ≥ 1.8) characterizing the protein subset exhibiting islet-promoting
regulation. (C) Top predicted activated upstream transcription regulators and graph depicting the number of relevant target DEPs in the HNF1A, HNF4A and FOXO3
network following a regulation toward islet abundance levels. (D) IPA generated hierarchical clustering of the predicted disease and function processes for the
conditions compared. (E) Selected signature-relevant DEPs exhibiting regulation toward islet abundance levels. (F) Selected top 5 organic network linking MECP2,
lipid and energy metabolism. Abbreviations: DEPs, differentially expressed proteins; FC, fold change; S5, stage 5 cells (pancreatic progenitor stage); 2w_postTX,
2 weeks following transplantation (differentiation in mice), Path, pathway; ROS, reactive oxygen species). For abbreviations see Supplementary Table S3.
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(Figure 4A). Of note, a bulk global proteomics comparison of
standard Matrigel-differentiated HNF1α1/+ (S7_HNF1α1/+)
and wild-type cells (S7_WT) revealed a decrease of all islet
hormone abundance in the HNF1α1/+ cells, especially
somatostatin (Figure 4B). Moreover, the key β-cell marker PDX1
(Pancreas/duodenum homeobox protein 1), the neuroendocrine
convertases PCSK1 and PCSK2 as well as the panendocrine
marker CHGA exhibited less abundance in the S7_HNF1α1/+
cells. Interestingly, MAFB, a transcription factor with essential
role for both human α- and β-cells displayed increased
abundance in the HNF1A deficient samples. As expected,
the upstream regulators analysis predicted the inactivation
of HNF1A (Supplementary Figure S2K). Interestingly, the
observed proteome landscape characterizing the HNF1α1/+
cells was also compatible with the inactivation of CDKN2A and
HNF4A (Supplementary Figure S2K), two upstream regulators
inferred above (Figure 3C) as activated in the healthy samples.
Furthermore, the proteome signature of the HNF1α1/+ was
consistent to the inactivation of PDX1 and PAX6 (Paired box
protein Pax-6), critical transcription factors for islet development
and cell fate selection (Supplementary Figure S2K).
Subsequently, the comparison of HNF1α1/+_cells and their
WT counterparts after xeno-transplantation did not reveal
a significant difference in the fraction of monohormonal
glucagon+ cells (Figure 4D, first graph). In contrast, the
proportion of the monohormonal insulin+ cells displayed a
steep decline in the transplanted HNF1α1/+ cells (Figure 4D,
middle graph). Importantly, the bihormonal fraction decrease
observed in the transplanted control was not recapitulated in the
HNF1α1/+-postTX cells (Figures 4C,D, last graph). Of note, the
WT and HNF1A1/+ S7-populations exhibited a similar fraction
of insulin+NKX6.1+ in two independent planar differentiation
rounds (Supplementary Figure S2L).
These results suggest that in vivo exposure promotes the
induction of a HNF1A-based mechanism, required for cell
fate restriction toward single-hormonal identity possibly by
regulating α-cell identity in β-cells.
We further investigated the role of HNF4A induction in
mediating the observed in vivo effect on cell fate restriction
by following the same experimental design as described above
(Figures 4E,F). In this case we employed previously generated
hiPSCs derived from patients (Vethe et al., 2017) bearing a
dominant heterozygous p.Ile271fs mutation in the coding
sequence of the HNF4A (Yamagata et al., 1996a; Fajans et al.,
2001). Similar to the above rationale, we expect that the in vivo
effect mediated induction of HNF4A-based mechanisms will
be suboptimal following the transplant. Large-scale imaging
microscopy revealed no significant change in the fractions
of monohormonal glucagon+, or monohormonal insulin+
cells in HNF4α1/+ condition before xenotransplantation
(Figure 4G). In contrast, following exposure to the in vivo
environment, the percentage of monohormonal insulin+ cells
was slightly increased in the transplanted HNF4α1/+ samples
(Figure 4H). Moreover, the total fraction of bihormonal cells
displayed a steep increase as compared to control transplanted
cells (Figures 4F,I). These results indicate that HNF4A
induction is required for the in vivo effect action on cell
fate restriction.
Of interest, the fraction of hormone+ cells is significantly
increased in the HNF4α1/+_postTX cells as compared to both
the control and HNF1α1/+_postTX (Figure 4J). In contrast,
in HNF1α1/+_postTX the proportion of hormone+ cells is
lower than in both control and HNF4α1/+_postTX. This result
advocates a possible role of the in vivo effect mediated HNF1A
and HNF4A induction on endocrine program commitment.
Taken together these data suggest that the host’ in vivo effect
requires the induction of both HNF1A and HNF4A in order to
restrict and control cell fate selection.
DISCUSSION
Here we investigated the impact of short-term intraperitoneal
xenotransplantation of encapsulated pancreatic progenitors. In
this study we report that the brief exposure to the in vivo
environment is insufficient for boosting the islet cell fraction,
yet it is beneficial for cell fate selection as indicated by a steep
decrease in the number of bihormonal cells and improved islet
proteome signature. Of note, the proportion of bihormonal
cells identified in the S7-population was more variable and
slightly higher than the one usually reported in the literature
(21.81 ± 13.2 vs. 20.2% previously reported in Rezania et al.
(2014). This is probably a repercussion of using planar culturing
conditions for the entire length of differentiation. We chose this
approach in order to avoid the confounding effect caused by
the switch to air-liquid interface (i.e. aggregation) characterizing
the last two stages of the original differentiation protocol
(Rezania et al., 2014).
Several works connected the bihormonal phenotype of
the in vitro differentiated cells to their immaturity status.
Consequently, the apparently subtle changes determining the
cells to exclusively select and express a single islet hormone
represent critical steps toward reaching the functionally mature
status previously reported after long-term transplantation
experiments (Rezania et al., 2014). It is tempting to speculate
that the rapid initiation of the underlying cell fate restriction
program following in vivo exposure could indicate an innate
defense mechanism protecting against the inclusion of aberrant
immature cells in adult host organisms. In addition, it should
be stated that the significant islet-profile enhancement following
transplantation does not necessarily involve a significant
functional improvement. Due to the inherent difficulties
in properly assessing the functionality of the encapsulated
differentiating cells, this particular parameter requires further
investigations. Nevertheless, it is, however, expected that a very
brief in vivo exposure, such as the one used in this study, will be
insufficient to promote any meaningful/detectable improvement
in the functionality of the transplanted cells. Indeed, previous
studies reported improved functionality and glucose stimulated
insulin secretion in similar setups only after about 60 days post
xenotransplantation (Rezania et al., 2014; Saber et al., 2018), thus
involving longer exposure times.
Moreover, we believe this is the first attempt to
comprehensively characterize the effect of the in vivo niche
on the transplanted cells. On a cautionary note, it should be
stated that the demultiplexing performed here is based on
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FIGURE 4 | Assessment of hormone expression patterns in differentiating cells characterized by suboptimal HNF1A or HNF4A levels. (A) Experimental workflow.
(B) Selected islet cell markers regulation in HNF1α1/+ (pool) following standard in vitro differentiation, identified by a pilot global proteomics experiment. (C) Confocal
imaging of insulin (green), glucagon (red) and DAPI (blue) immunofluorescence staining of encapsulated HNF1α1/+ and WT cells following transplantation.
(D) Manual counting of the proportion of monohormonal glucagon+ cells, monohormonal insulin+ cells and bihormonal glucagon+ insulin+ in encapsulated
HNF1α1/+ and WT samples before and after in vivo exposure (n = 7,8,8,7). (E) Experimental workflow. (F) Confocal imaging of insulin (green), glucagon (red) and
DAPI (blue) immunofluorescence staining of encapsulated HNF1α1/+ and WT cells following transplantation. (G,H) The proportion of monohormonal glucagon + and
monohormonal insulin + cells in HNF4α1/+ and WT samples (G) before (n = 9,5,9,5) and after (H) transplantation (n = 26,6,26,6) quantified by Imaris software.
(I) The fraction of bihormonal glucagon+ insulin+ cells in HNF4α1/+ and WT samples after transplantation (n = 26,6). (J) The fraction of total hormonal+ cells in WT,
HNF1α1/+ and HNF4α1/+ samples after transplantation. Scale bars: 100 µm and 50 µm (high magnifications). Graphs data are shown as mean and SD. *p < 0.05,
**p < 0.01, ***p < 0.001, ****p < 0.0001 (Mann–Whitney test). Abbreviations: DEPs, differentially expressed proteins; FC, fold change; WT, wild type; D, mutated
allele; S5_WT, control stage 5 cells; S5_HNF1α, Stage 5 cells bearing the HNF1α1/WT mutation; WT_postTX, control cells following transplantation, HNF1α1/WT
_postTX, HNF1α1/WT cells after transplant; S5_HNF4α, Stage 5 cells bearing the HNF4α1/WT mutation; HNF1α1/WT _postTX, HNF1α1/WT cells after transplant.
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the premise that the three effects considered are independent
variables. Essentially, it presumes that the encapsulation effect
is similar in vitro and in vivo and thus, the differences between
the two contexts are individually prompted by either the
differentiation cocktail or the in vivo niche. Although this
assumption is required for executing the analysis, the possibility
that encapsulation effects vary between in vitro and in vivo
environments should be kept in mind. Several previous studies
reported increased starvation/hypoxia-based oxidative stress
in encapsulated native human islets, as well as aggregated cells
(Jacobs-Tulleneers-Thevissen et al., 2013; Weir, 2013; Barra
and Tse, 2018; Evron et al., 2018), likely due to capsule’s size
and density of the encapsulated structure. Yet, our analysis
indicated that the observed changes in the redox balance
are consistent with a more islet-like fingerprint, suggesting
that single cells in suspension benefit of improved nutrient
and oxygen exposure. In contrast, the proteins defining the
neuro/neuritogenesis signature did not display a regulation
pattern compatible with islet cell fate acquisition in response to
the in vivo environment, suggesting the occurrence of additional
processes following transplantation. Of interest, a substantial
amount of research generated by the transplantation under the
kidney capsules of native pancreatic islets/islet cells, reported
the rapid vascularization (Brissova et al., 2004; Morini et al.,
2007; Nyqvist et al., 2011) and innervation of the graft (Korsgren
et al., 1992, 1993). One study showed that the sympathetic
reinnervation paralleled the timeline of revascularization, with
axons visible inside the islet grafts at 15 days post-transplant,
closely associated with blood vessels (Rodriguez-Diaz et al.,
2012). Although no study investigated the reinnervation of
the encapsulated islets/cells, a similar mechanism might occur
following xenotransplantation of encapsulated differentiating
cells, possibly initiated by neuritogenic signals generated by
the grafted cells.
Furthermore, the upstream regulators analysis predicted the
activation of HNF1A transcription factor as top hit responsible
for the proteome landscape observed in response in vivo
environment. Interestingly, HNF1A is a transcriptional regulator
with strong bounds with islet cell fate and functionality
(Yamagata et al., 1996b; Wang et al., 1998, 2000; Haliyur et al.,
2019). Of interest, a recent study on genetically modified ESCs
via CRISPR/CAS9 system showed that loss of HNF1A leads
to increased expression of α-cell markers (including glucagon),
coupled with decreased expression of β-cells markers such
as PAX4 (Paired box protein Pax-4). Furthermore, functional
defects in both glycolysis and mitochondrial function were also
detected upon HNF1A ablation (Cardenas-Diaz et al., 2019).
Here we show that the in vivo niche effect on transplanted
cells requires both HNF1A and HNF4A induction. Our data
suggest a potential cooperative, however, not overlapping role
of the two effect regulators in restricting and maintaining the
hormone expression choice. In this specific context, suboptimal
HNF1A stimulation coupled with efficient in vivo HNF4A
induction hinders the effect of in vivo niche on both cell identity
restriction and, possibly, endocrine program commitment.
Correspondingly, suboptimal HNF4A stimulation connected
with the efficient in vivo HNF1A induction leads to an increased
recruitment of endocrine cells characterized by an immature,
bihormonal, profile. This interplay indicates that, besides the
obvious importance of the optimal HNF1A and HNF4A
induction, the ratio between the expression levels is also critical
for mediating the in vivo effects on islet cell identity. Certainly,
establishing HNF1A and HNF4A specific roles in controlling islet
cell identity and especially endocrine commitment will require
complex future in vivo/in vitro investigations into demultiplexing
the intricate HNF1A-HNF4A axis. Moreover, the in vivo factor/s
responsible for their induction are not known. Identification of
these signal/s, besides improving the knowledge of the cellular
and molecular basis of islet cell identity regulation, might benefit
the current differentiation and regeneration strategies.
Based on the above results, we advance a model in which
immediately after transplantation the in vivo environment
promotes the islet profile in the differentiating pancreas
progenitor cells, manifested by ameliorating their hormone
expression phenotype. This probably occurs via an improved
energy metabolism influencing the activity of specific epigenetic
modifiers, such as MECP2. The underlying mechanism is at
least partially dependent on the optimal levels of HNF1A and
HNF4A, as decreased expression of these transcription factors
not only cancel the observed confinement toward single hormone
expression but also triggers an accumulation of immature
bihormonal cells.
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